missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Felvizumab Recombinant Human Monoclonal Antibody (RSHZ19 (Felvizumab))
Human Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA548053
This item is not returnable.
View return policy
Description
Specificity: This antibody is specific for the an epitope located between amino acids 417-432 of conserved fusion (F) protein of RSV.
Felvizumab is a biosimilar that targets RSV. Human respiratory syncytial virus (RSV) is a member of the Paramyxoviridae family, subfamily Pneumovirinae, that causes common respiratory tract infections such as measles and mumps. Its genome consists of single stranded, negative sense RNA that encodes three envelope glycoproteins, a small hydrophobic (SH) protein of unknown function, a major glycoprotein (G) known as the attachment protein, and a fusion (F) protein. Its name comes from the fact that F proteins on the surface of the virus cause the membranes on nearby cells to merge, forming syncytia. While RSV typically produces mild symptoms in adults, it is one of the leading causes of lower respiratory tract infections and hospital visits during infancy and childhood.
Specifications
| Felvizumab | |
| Recombinant Monoclonal | |
| 1 mg/mL | |
| PBS with 0.02% ProClin 300 | |
| Human | |
| Protein A | |
| RUO | |
| Virus | |
| Antibody | |
| IgG1 κ |
| ELISA, Functional Assay | |
| RSHZ19 (Felvizumab) | |
| Unconjugated | |
| SB 209763 | |
| This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework. | |
| 200 μg | |
| Primary | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction